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http://dx.doi.org/10.1016/j.jmii.2012Background/Purpose: Serratia marcescens is a rare pathogen of central nervous system infec-
tions. This study was to investigate the epidemiology, prognostic factors, and treatment
outcomes of S. marcescens meningitis.
Methods: This retrospective analysis included 33 patients with culture-proven S. marcescens
meningitis hospitalized between January 2000 and June 2011.
Results: Of the 33 patients enrolled, only one did not receive neurosurgery before the onset of
S. marcescens meningitis. Patients with S. marcescens meningitis had higher ratios of brain
solid tumors (54.5%) and neurosurgery (97.0%) with a mortality rate of 15.2%. The mean
interval between the first neurosurgical procedure and the diagnosis of meningitis was 17.1
days (range, 4e51 days). Only one third-generation cephalosporin-resistant S. marcescens
isolate was recovered from the patients’ cerebrospinal fluid (CSF) specimens. Compared with
the favorable outcome group (nZ 20), the unfavorable outcome group (nZ 13) had a higher
percentage of brain solid tumors, more intensive care unit stays, and higher Sequential Organ
Failure Assessment score, CSF lactate and serum C-reactive protein concentrations at diagnosis
of meningitis. Under the multiple regression analysis, CSF lactate concentration 2-fold the
upper limit of normal (ULN) was independently associated with unfavorable outcomes (odds
ratio, 7.20; 95% confidence interval, 1.08e47.96; p Z 0.041).
Conclusion: S. marcescens meningitis is highly associated with neurosurgical procedures for
brain solid tumors. CSF lactate concentration 2x ULN may predict an unfavorable outcome.fectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital, 5 Fu-Shin Street,
com (M.-H. Lee).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
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260 Y.-M. Wu et al.Its mortality is not high and empiric treatment with parenteral third-generation cephalosporins
may have a satisfactory clinical response.
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reserved.Introduction meningitis episodes due to a different bacterial pathogen
after the completion of therapy for the initial episode, or dueSerratia marcescens, a species of Gram-negative bacillus of
the Enterobacteriaceae,1 is distributed widely in the hospital
environment and has been recognized as an opportunistic
pathogen causing a variety of nosocomial infections, including
wound infections,2,3 urinary tract infections,3,4 pneumonia,3
bacteremia,3,5,6 endocarditis,7 and myocarditis.8
However, it is a rare pathogen of central nervous system
(CNS) infections. There were only case reports in patients
with a history of head trauma, neurosurgical procedures,
mastoiditis or chronic sinusitis.9e13 Prosthetic devices,
including external cerebrospinal fluid (CSF) drainage cath-
eters14 and ventriculoperitoneal (VP) shunts,11,15 facilitate
bacterial colonization and provide a potential route into
the CNS, eventually causing meningitis. The use of external
ventricular drains (EVDs) or VP shunts might develop an
environment associated with a relatively high risk for post-
neurosurgical CNS infections.
In a previous study regarding post-neurosurgical menin-
gitis, S. marcescens was the most common Gram-negative
pathogen, accounting nearly 10% of the total 69 identified
isolates.16 However, the literature concerning the risk
factors, impacts of antimicrobial therapy and clinical
outcomes for S. marcescens meningitis were limited.
Hence, we conducted this retrospective study to investi-
gate the epidemiology, prognostic factors, and treatment
outcomes of S. marcescens meningitis.
Materials and methods
Study design, patients and case definition
This retrospective study was conducted at the Chang Gung
Memorial Hospital-Linkou, a 3715-bed university-affiliated
hospital and tertiary referral medical center in northern
Taiwan. This study has been approved by the Institutional
Research Board of CGMH-Linkou (Number: 101-0477B).
Through the computer-assisted microbiology databases, all
patients with CSF cultures positive for S. marcescens
between January 2000 and June 2011 were reviewed.
The diagnostic criteria for S. marcescens meningitis were
based on the isolation of S. marcescens from 1 CSF cultures
with at least one of the following findings consistent with
meningitis: (1) clinical manifestations, such as fever, seizure,
altered consciousness, or signs of meningeal irritation; and
(2) laboratory evidence, including a decreased CSF glucose
concentration (CSF/serum glucose ratio 0.4 or CSF glucose
<40 mg/dL if serum glucose was not available), increased
lactate (>36mg/dL) andprotein (>32mg/dL) concentrations,
and pleocytosis ( 10 white blood cell/mL) with neutrophil
predominance.16e18 Patients were excluded if S. marcescens
was isolated from a CSF culture without any clinical feature
consistentwithmeningitis, orwithout clinical deterioration in
the absence of appropriate antibiotic treatment for 3 days or
more.19 “Recurrence” was defined as a second or furtherto S. marcescens 3 weeks or more after the completion of
therapy for the first episode. “Relapse” of meningitis was
considered if it was also caused by S. marcescens within 3
weeks of the completion of therapy for the initial episode.16,20
Descriptive epidemiology
Data collected from the enrolled patients included demo-
graphics, comorbid illnesses, clinical presentations and diag-
noses, neurosurgeries in recent 3 months, laboratory data,
severity of illness [Glasgow Coma Scale (GCS) score and
Sequential Organ Failure Assessment (SOFA) score],21 treat-
ment courses and outcomes. Comorbid illnesses included
diabetes mellitus, hepatic dysfunction (defined as the serum
total bilirubin level 2.0 mg/dL or liver cirrhosis), renal
insufficiency (defined as a serum creatinine level2.0mg/dL
or a requirement of hemodialysis), chronic lung diseases,
heart failure, and hematologic or solid organ malignancies.
Microbiologic analysis
Blood cultures were processed in the clinical microbiology
laboratory, using the BACTEC 9240 blood culture system
(Becton Dickinson Diagnostic Instrument System, USA).
S. marcescens isolates were identified on the basis of the
following properties: aerobic, Gram-negative bacilli on
aGram’s stainwith an indole-negative, lysinedecarboxylase-
positive, and ornithine decarboxylase-positive reaction.1 Its
fermentation reactions in commercial identification system
wereacidproduced fromsucroseandD-sorbital, butnot from
arabinose, L-rhamnose, D-xylose, cellobiose, and D-arabi-
tol.1 Antimicrobial susceptibility testingwasperformedusing
the disk diffusion method according to Clinical and Labora-
tory Standards Institute criteria.22
Treatment and outcomes
Appropriate antibiotic treatment was defined as the use of
one or more antimicrobial agents proved to be active
against S. marcescens in vitro and capable of passing
through the blood-brain barrier in adequate concentra-
tions.14,19 The predominant antibiotic regimen was defined
as the antibiotic used for at least two-thirds of the patient’s
treatment course.14
Clinical outcomes were determined by the GCS change
andmortality. A favorable outcomewas considered if theGCS
scorewas unchangedor increased at the treatment endpoint,
while an unfavorable outcome was considered if there was
a decreased GCS score at the treatment endpoint. Treatment
endpoint was the timing of discontinuation of therapy for
S. marcescens meningitis. We defined the mortality attrib-
utable to meningitis if the patient’s death was due to the
meningitis or its complications.19 Microbiologic outcomes
were determined by the interval to CSF sterilization and the
recurrence or relapse of S. marcescens meningitis.
Table 1 Demographic and clinical characteristics of 33
patients with Serratia marcescens meningitis
Characteristics Value
Age, y 49.6  24.7
Male 20 (60.6)
Comorbid illness
Benign or malignant brain tumor 18 (54.5)
Diabetes mellitus 5 (15.2)
Chronic lung disease 3 (9.1)
Hepatic dysfunction 1 (3.0)
Heart failure 1 (3.0)
Hematologic malignancy 1 (3.0)
Renal insufficiency 0 (0.0)
Types of infections
Spontaneous 1 (3.0)
Postneurosurgery 32 (97.0)
Neurosurgical conditions (n Z 32)
Tumors 16 (50.0)
Hemorrhagic
cerebrovascular accident
5 (15.6)
Traumatic brain injury 5 (15.6)
Othersa 6 (18.8)
Frequencies of neurosurgery
before meningitis within 3 mos
1.6  1.7
Interval between meningitis
and the initial neurosurgery, d
17.1  15.1
a Others included brain abscess, epidural abscess, hydro-
cephalus, ventriculitis, and subdural effusion.
Data presented as n (%) or mean  standard deviation.
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Statistical analyses were done using IBM Statistical Package
for the Social Sciences version 18.0 (SPSS Inc., Somers, NY,
USA). Univariate analyses were performed with the chi-
square test or Fisher’s exact test for categorical variables,
and the Student’s t test or Wilcoxon test for continuous
variables, as appropriate. Odds ratio (OR) and 95% confi-
dence interval (CI) were calculated to evaluate the strength
of any associations as well as the precision of the estimate of
effect in the outcome analyses. Variables with a two-tailed p
value <0.05 were entered to a backward multivariate
logistic regression model to determine the factors indepen-
dently associated with unfavorable outcome. A two-tailed p
value <0.05 was considered statistically significant.
Results
Descriptive epidemiology
During the 10-year period of the study, 34 patients had
S. marcescens isolated from at least one CSF specimens. Of
the 34 patients identified, 33 met the diagnostic criteria and
one was contaminant. Of the 33 enrolled patients, 20 were
males and 13 were females, with a mean age of 49.6 years
(range, 1 month to 86 years old). Of them, 6 (18.2%) did not
have any comorbid illness. The first three most common
comorbid illnesses were benign or malignant brain tumors
(18 patients, 54.5%), followed by diabetes mellitus (five,
15.2%) and chronic lung diseases (three, 9.1%). Only one
patient did not receive neurosurgical intervention before the
onset of meningitis. Patients’ demographics, associated
neurosurgical conditions, and comorbid illnesses are listed in
Table 1. The most common neurosurgical conditions were
benign or malignant brain tumors (16, 50.0%), followed by
hemorrhagic cerebrovascular accidents (five, 15.6%).
The mean interval between the first neurosurgical
procedure and the diagnosis of meningitis was 17.1 days
(range, 4e51 days). The mean time from the diagnosis of
S. marcescens meningitis to adequate treatment was 2.8
days (range, 0e27 days), and 18 patients (54.5%) received
appropriate antimicrobial therapy within 48 hours of the
diagnosis of S. marcescens meningitis. Twenty-eight
patients had two or more additional CSF cultures per-
formed after the diagnosis of S. marcescens meningitis, and
the mean interval to CSF sterilization was 15.2 days (range,
3e43 days). In this study, 20 patients (60.6%) had a favor-
able outcome, while 13 (39.4%) had an unfavorable
outcome. Overall, five patients (15.2%) died in the hospital;
one died of meningitis, and the other four died of their
comorbidities (e.g., nosocomial pneumonia) or the under-
lying neurosurgical conditions (e.g., intracranial malig-
nancy) despite CSF sterilization from meningitis.
Clinical and laboratory characteristics of
S. marcescens meningitis
The clinical features, laboratory data and outcomes of
S. marcescens meningitis are summarized in Table 2. Two
major initial clinical manifestations were fever (30 patients,
90.9%) and altered consciousness (20, 60.6%). CSFabnormalities at the onset of S. marcescens meningitis
included pleocytosis (mean, 6510 cells/mL, with 75% poly-
morphonuclear leukocytes), decreased CSF glucose concen-
tration (mean, 36.8 mg/dL), elevated CSF protein
concentration (mean, 534.6mg/dL), andelevatedCSF lactate
concentration (mean, 107.2 mg/dL). Twenty-one patients
(84.0%) had a positive Gram’s staining, and two (6.1%) had
polymicrobial infections, including one co-infected with
Pseudomonas aeruginosa and the other co-infected with
Acinetobacter baumannii. There were five patients with
concomitant S. marcescens bacteremia, two with concurrent
pneumonia, and two with intra-abdominal infections. The
average scores of GCS and SOFA were 13.3 and 3.5 at the
diagnosis of meningitis, respectively. The overall all-cause
mortality of patients in this study was 15.2% (5/33).
Twenty-eight patients had brain CT scans or magnetic
resonance imaging48 hours before or after the diagnosis of
S. marcescens meningitis, and two of them had negative
findings. Positive image findings were as follows: hydro-
cephalus (18, 64.3%), midline shift (10, 35.7%), brain
abscess (5, 17.9%), infarction (4, 14.3%), and lep-
tomeningeal enhancement (1, 3.6%).Risk factors for unfavorable outcomes
All the 33 enrolled patients had aGCS score>3 at the onset of
S. marcescens meningitis. The analysis of potential risk
factors for unfavorable outcome is listed in Table 3.
Table 2 Clinical features, laboratory data, and outcomes
of patients with S. marcescens meningitis
Variables Value
Initial clinical presentations
Fever 30 (90.9)
Altered consciousness 20 (60.6)
Nausea or vomiting 12 (36.4)
Seizure 9 (27.3)
Respiratory failure 7 (21.2)
Headache 6 (18.2)
Neck stiffness 3 (9.1)
Shock 2 (6.1)
Cerebrospinal fluid data
Leukocyte count (mL) 6510.1  21,600.8
Glucose level (mg/dL) 36.8  32.4
Protein level (mg/dL) 534.6  984.6
Lactate level (mg/dL) 107.2  66.4
Positive Gram’s stain result (n Z 25) 21 (84.0)
Peripheral blood study
Leukocyte count (1000/mL) 15.2  6.3
C-reactive protein (mg/L) 145.3  116.2
Concomitant bacteremia 5 (15.2)
Microbiologic data of cerebrospinal fluid
Polymicrobial 2 (6.1)
Severity of illness scoring at the onset
GCS score 13.3  2.7
SOFA score 3.5  2.5
Intensive care unit stay 22 (66.7)
Duration of therapy 47.6  25.6
Outcome
Attributable mortality 1 (3.0)
All-cause mortality 5 (15.2)
Data presented as n (%) or mean  standard deviation.
GCS Z Glasgow Coma Scale; SOFA Z Sequential Organ Failure
Assessment.
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brain tumors, twofold elevation of CSF lactate concentration
above upper limit of normal (ULN), higher serum C-reactive
protein (CRP) levels (>5 mg/L), more ICU stays, and higher
SOFA score at the onset of S. marcescens meningitis were
significantly associatedwith unfavorable outcomes. Diabetic
patients had the trend towards unfavorable outcomes, but
the difference was not statistically significant.
Variables in multivariate analysis included benign or
malignant brain tumors, CSF lactate 2x ULN, and SOFA
score at the onset of S. marcescens meningitis. After
analysis of aforementioned variables, CSF lactate 2x ULN
(odds ratio, 7.20; 95% CI, 1.08e47.96; p Z 0.041) was
independently associated with unfavorable outcomes for
patients with S. marcescens meningitis.Antimicrobial therapy and outcomes
There were two patients with recurrence of meningitis, and
no patient had relapsed S. marcescens meningitis. The firstpatient was a 1-month-old premature female infant with
spontaneous S. marcescens meningitis and initially pre-
senting with fever and seizure. Her computed tomography
(CT) revealed hydrocephalus and ventriculitis. She received
patent ductus arteriosus ligation 18 days before the episode
of S. marcescens meningitis. Third-generation cephalospo-
rins were administered intravenously 48 hours after the
onset of meningitis, and had been used for 52 days in total.
CSF sterilization was achieved 7 days after initiation of
treatment. EVD was also performed for increased intra-
cranial pressure. However, infection recurred 2 weeks after
the completion of therapy for the initial episode, and the
recurrent meningitis was caused by Klebsiella oxytoca.
Another course of antibiotic therapy with third-generation
cephalosporins was initiated, and she recovered from the
recurrent meningitis.
The second patient with recurrence of S. marcescens
meningitis was a 45-year-old male receiving craniectomy
for removal of brain trigeminal schwannoma 8 days before
the onset of S. marcescens meningitis. Initial presentations
were fever and altered consciousness. Treatment with
intravenous third-generation cephalosporin lasted for 46
days, and he also had the surgical debridement and EVD
revisions twice. CSF sterilization was achieved 16 days after
diagnosis. He had S. marcescens CNS infection again around
2.5 months after the completion of therapy for the first
episode. His second episode was presented as an epidural
abscess. He was retreated with surgical debridement and
third-generation cephalosporin, which resulted in a favor-
able outcome.
Of the 33 patients enrolled, only one third-generation
cephalosporin-resistant S. marcescens isolate was recov-
ered, which was collected from subdural empyema occur-
ring 2 months after initial craniotomy. All patients received
appropriate intravenous antibiotic treatment and none of
them was treated with intrathecal antibiotics. Twenty-
seven patients (81.8%) received monotherapy with third-
generation cephalosporins, while six patients (18.2%)
received meropenem or imipenem. No seizures were
observed in any of the patients who received carbapenem
therapy.
Carbapenems and third-generation cephalosporins, such
as ceftriaxone, ceftazidime and flomoxef, were the most
frequently used antibiotics. Patients treated with third-
generation cephalosporins had a shorter mean time to CSF
sterilization than carbapenems (14 vs. 33 days, pZ 0.021),
but the duration of therapy, unfavorable outcome, and
mortality had no statistical difference between these two
different classes of antimicrobial agents (Table 4).Discussion
To thebestofour knowledge, this is the largest study regarding
S.marcescensmeningitis in theEnglish literature. In this study,
cases occurred sporadically over a 10-year period, and all the
enrolled patientswere hospitalized at differentwards or ICUs,
so outbreak of S.marcescensmeningitis was not likely. Most of
the patients in this study had neurosurgical intervention,
accounting for 97.0% (32/33) of total cases. Compared with
other Gram-negative meningitis, S. marcescens meningitis
occurred more frequently in post-neurosurgical patients
Table 3 Univariate analysis of risk factors for unfavorable outcome
Outcomes Favorable
outcomea (n Z 20)
Unfavorable
outcomeb (n Z 13)
p
Age, y 43.60  27.32 58.77  17.18 0.085
Male 11 (55.0) 9 (69.2) 0.414
Comorbid illness
Benign or malignant brain tumor 8 (40.0) 10 (76.9) 0.037*
Diabetes mellitus 1 (5.0) 4 (30.8) 0.066
Chronic lung disease 3 (15.0) 0 (0.0) 0.261
Hepatic dysfunction 0 (0.0) 1 (7.7) 0.394
Heart failure 1 (5.0) 0 (0.0) >0.99
Hematologic malignancy 1 (5.0) 0 (0.0) >0.99
Laboratory data
CSF glucose (mg/dL) 44.63  32.41 26.25  30.64 0.138
CSF protein (mg/dL) 579.88  1228.29 466.66  464.26 0.764
CSF lactate 2x ULN 5 (35.7)c 9 (81.8)d 0.042*
Blood leukocyte count (1000/mL) 15.0  6.2 15.6  6.6 0.778
Serum CRP (mg/L) 103.71  74.47 211.96  142.21 0.017*
Na (meq/L) 135.21  7.04 137.69  4.73 0.276
Risk factors
Polymicrobial meningitis 1 (5.0) 1 (7.7) >0.99
Frequencies of neurosurgery before
meningitis within 3 mos
1.25  1.33 2.15  2.15 0.145
ICU stay 10 (50.0) 12 (92.3) 0.022*
Concomitant bacteremia 3 (15.0) 2 (15.4) >0.99
Treatment
CSF sterilization 17 (100.0)f 9 (100.0)g d
Interval to CSF sterilization, d 12.29  7.03 20.67  13.37 0.045*
Time to adequate treatment, d 1.94  2.79 4.45  8.04 0.244
Adequate treatment within 72 hrs 14 (70.0) 6 (46.2) 0.171
SOFA score at the onset 2.69  2.27 4.54  2.47 0.048*
Cathetere 15 (75.0) 9 (69.2) >0.99
Removal or revision of catheterse 14 (93.3)h 8 (88.9)i 0.620
Time to removal or revision of catheters, d 4.13  5.03 1.90  4.31 0.259
Time from diagnosis to discharge, d 51.55  28.30 111.15  40.43 < 0.001*
Outcome
Alive 20 8 0.005*
Succumbed to the disease 0 1
a Favorable outcome: “unchanged or increased GCS score” at the end of treatment for meningitis.
b Unfavorable outcome: “decreased GCS score” at the end of treatment for meningitis.
c 14 in 20 patients had such study.
d 11 in 13 patients had such study.
e Catheter: external ventricular drain or ventriculoperitoneal shunt.
f 17 in 20 patients had such study.
g 9 in 13 patients had such study.
h 15 in 20 patients had catheters.
i 9 in 13 patients had catheters.
Data presented as n (%) or mean  standard deviation.
*Statistically significant (p < 0.05).
CRP Z C-reactive protein; CSF Z cerebrospinal fluid; ICU Z intensive care unit; SOFA Z sequential organ failure assessment;
ULN Z upper limit of normal.
Serratia marcescens meningitis 263(97.0% vs. 33.3e84.6%).23e36 This result may alert neurosur-
geons the bacteriology of postneurosurgical bacterial menin-
gitis. These CNS infections due to S. marcescens had quite
variable clinical presentations ranging from surgical wound or
ventricular shunt infections to deeply localized abscess
formation in brain parenchyma, epidural space, or bone-flap.The second characteristic finding distinguishing our
study from previous studies for Gram-negative meningitis is
the higher percentage of benign or malignant brain tumor
(54.5% versus 0e26.7%).23e26 The relationship between S.
marcescens infections and malignancy has been reported by
Haddy et al.27 They presented a study of S. marcescens
Table 4 Antimicrobial regimens for the treatment of S. marcescens meningitis and clinical outcomes
Predominant antimicrobial
regimen (monotherapy)
Third-generation
cephalosporins (n Z 27)
Carbapenems
(n Z 6)
p
Interval to sterile CSF culture, mean d (range) 14 (4e44) 33 (4e51) 0.021*
Duration of therapy, mean d (range) 45 (5e102) 57 (31e99) 0.329
Unfavorable outcome, n (%) 10 (37.0) 3 (50.0) 0.659
Mortality, n (%) 3 (11.1) 2 (33.3) 0.216
* Statistically significant (p < 0.05).
CSF Z cerebrospinal fluid.
264 Y.-M. Wu et al.bacteremia and found 20% of the patients had advanced
malignancy. Besides, S. marcescens meningitis had a lower
mortality than other Gram-negative meningitis (15.2% vs.
21.0e40.0%).23e26
Patients’ GCS scores are the important prognostic vari-
ables for bacterial meningitis.14,28 The comparison of GCS
change between the onset of S. marcescens meningitis and
at the end of treatment for meningitis could be more
practical for physicians to predict the prognosis. CSF
lactate is a good indicator in clinical practice to distinguish
bacterial meningitis from aseptic meningitis in combination
with other CSF characteristics.18,29,30 It is also a quick,
sensitive, and specific test to identify patients with post-
neurosurgical bacterial meningitis.31 Besides, from
a meta-analysis of 25 previous studies, its diagnostic
accuracy was higher than that of conventional markers
(i.e., CSF Gram’s stain, CSF leukocyte counts, CSF glucose,
CSF/plasma glucose ratio, and CSF protein).30 The role of
CSF lactate level in predicting prognosis of bacterial
meningitis is still conflicting.29,32,33 In this study, CSF
lactate level 2x ULN (cutoff, 72 mg/dL) was proved to be
a valid ancillary test in predicting unfavorable outcomes for
patients with S. marcescens meningitis.
Recent epidemiologic data showed an increasing
frequency of antimicrobial resistance among S. marcescens
isolates.34e36 In this study, 32 S. marcescens isolates from
initial positive CSF sampling were all susceptible to cef-
triaxone, ceftazidime, imipenem, amikacin, and genta-
micin, and 31of themwereobtained frompost-neurosurgical
patients. Resistance to third-generation cephalosporins was
only detected in one CSF isolate. Antibiotic therapy with or
without neurosurgical intervention (i.e., shunt removal and/
or abscess drainage) was the mainstay of treatment for our
patients. Compared with carbapenems, third-generation
cephalosporins had a shorter mean time to CSF sterilization
(14 vs. 33 days, pZ 0.021). Nevertheless, this phenomenon
was not observed in patientswith Enterobactermeningitis.12
In a review of the treatment strategies for CSF shunt infec-
tions, retention of the shunt resulted in poor cure rates
regardless of whether there was the use of intravenous
antibiotics alone (cure rate of 24%) or with concurrent
intrathecal antibiotics (cure rate 40%). In the treatment of
secondary infection of an external ventricular device,
removal of the devicewas required.37 In this study, therewas
no significant difference in the outcome no matter what
neurosurgeons did the removal or revision of external CSF
drainage catheters or VP shunts (Table 3).
This study has limitations for its retrospective design and
the small number of patients studied. However, theinfrequent nature of this infection makes prospective
evaluation very difficult. In addition, although this is the
largest reported series of S. marcescens meningitis to date,
the single-institution setting may limit the generalizability
of the findings.
In conclusion, a neurosurgical procedure for brain solid
tumor has the potential for the development of
S. marcescens meningitis. The overall mortality of
S. marcescens meningitis is around 15%. CSF lactate
concentration 2x ULN is independently associated with
an unfavorable outcome. Most of the S. marcescens CSF
isolates were still susceptible in vitro to third-generation
cephalosporins over a 10-year period, and the empiric
therapy with parenteral third-generation cephalosporins
yielded satisfactory results.References
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